See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

MAIA Biotechnology Doses First Patient in Expansion of Phase II Lung Cancer Trial

Summary by Clinical Trials Arena
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.The post MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Clinical Trials ArenaClinical Trials Arena

MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.The post MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial appeared first on Clinical Trials Arena.

Read Full Article
channelchek.comchannelchek.com

Release - MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer - Channelchek

Open the article to view the coverage from channelchek.com

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

channelchek.com broke the news in on Wednesday, July 9, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Taiwan icon

Taiwan

News
For You
SearchBlindspotLocal